0001104659-23-084444.txt : 20230726 0001104659-23-084444.hdr.sgml : 20230726 20230726200020 ACCESSION NUMBER: 0001104659-23-084444 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230717 FILED AS OF DATE: 20230726 DATE AS OF CHANGE: 20230726 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sarchi Christopher CENTRAL INDEX KEY: 0001986597 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38596 FILM NUMBER: 231114973 MAIL ADDRESS: STREET 1: C/O REPLIMUNE GROUP, INC. STREET 2: 500 UNICORN PARK DRIVE CITY: WOBURN STATE: MA ZIP: 01801 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Replimune Group, Inc. CENTRAL INDEX KEY: 0001737953 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 822082553 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: (781) 222-9600 MAIL ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 3 1 tm2322141-1_3seq1.xml OWNERSHIP DOCUMENT X0206 3 2023-07-17 0 0001737953 Replimune Group, Inc. REPL 0001986597 Sarchi Christopher C/O REPLIMUNE GROUP, INC. 500 UNICORN PARK DRIVE WOBURN MA 01801 0 1 0 0 Chief Commercial Officer Common Stock 55000 D Common Stock 22500 D Employee Stock Option (right to buy) 27.20 2032-12-30 Common Stock 82500 D Employee Stock Option (right to buy) 17.66 2033-04-01 Common Stock 33750 D Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The Reporting Person was granted 55,000 RSUs on December 30, 2022, 25% of such RSUs will vest on November 15, 2023, and the remainder will vest in three approximately equal annual installments thereafter until November 15, 2026, subject to the Reporting Person's continuous service to the Issuer. Represents shares of the Issuer's common stock issuable upon settlement of RSUs granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The Reporting Person was granted 22,500 RSUs on April 1, 2023, 25% of such RSUs will vest on May 15, 2024, and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2027, subject to the Reporting Person's continuous service to the Issuer. 25% of the shares underlying this stock option vest on December 30, 2023, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. 25% of the shares underlying this stock option vest on April 1, 2024, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Exhibit List Exhibit 24 - Power of Attorney /s/ Shawn Glidden, as attorney-in-fact 2023-07-26 EX-24 2 tm2322141d1_ex24.htm EXHIBIT 24

Exhibit 24

POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of Shawn Glidden and Philip Astley-Sparke, signing singly, as his true and lawful attorney-in-fact to:

(1)            execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer of Replimune Group, Inc. (the “Company”), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder and any other forms or reports the undersigned may be required to file in connection with the undersigned’s ownership, acquisition, or disposition of securities of the Company;

(2)            do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, or other form or report, and timely file such form or report with the U.S. Securities and Exchange Commission and any stock exchange or similar authority; and

(3)            take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorneys-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorneys-in-fact on behalf of the undersigned, pursuant to this Power of Attorney, shall be in such form and shall contain such terms and conditions as such attorneys-in-fact may approve in his or her discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform each and every act and thing whatsoever requisite, necessary, and proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorneys-in-fact, or his or her substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that no such attorney-in-fact, in serving in such capacity at the request of the undersigned, is hereby assuming any of the undersigned’s responsibilities to comply with Section 13 and Section 16 of the Securities Exchange Act of 1934 and the rules thereunder, as amended.

This Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

[Signature Page Follows]

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 14^th day of July, 2023.

	/s/ Christopher Sarchi
	Christopher Sarchi